These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17722856)

  • 1. EPO use: let the patients be involved in the decision.
    Peters KK
    Nephrol News Issues; 2007 Aug; 21(9):49-50. PubMed ID: 17722856
    [No Abstract]   [Full Text] [Related]  

  • 2. Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
    Holloway M
    Nephrol Nurs J; 2007; 34(5):527-31. PubMed ID: 18041455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative mortality and epoetin alpha dose among hemodialysis patients.
    Coyne DW
    Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
    [No Abstract]   [Full Text] [Related]  

  • 4. Relative mortality and epoetin alpha dose in hemodialysis patients.
    Cotter DJ; Thamer M; Zhang Y
    Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoietin for end-stage renal disease.
    Adamson JW; Eschbach JW
    N Engl J Med; 1998 Aug; 339(9):625-7. PubMed ID: 9718384
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-weekly erythropoietic therapy: is there a difference between the available preparations?
    Weiss LG
    Nephrol Dial Transplant; 2004 May; 19(5):1330-1; author reply 1331. PubMed ID: 15102981
    [No Abstract]   [Full Text] [Related]  

  • 8. Is it time to reconsider subcutaneous administration of epoetin?
    Patel TV; Robinson K; Singh AK
    Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment.
    Stasko J; Galajda P; Ivanková J; Hollý P; Rozborilová E; Kubisz P
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):410-5. PubMed ID: 17911193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor.
    Kumchev E; Koytchev R; Dimitrakov D; Stavrev P; Tsochev G; Siebert-Weigel M
    Adv Ther; 2008 Dec; 25(12):1375-8. PubMed ID: 19043680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of low dosages of epoetin alfa in dogs.
    Allen AG
    J Am Vet Med Assoc; 1997 Dec; 211(12):1504-5. PubMed ID: 9412672
    [No Abstract]   [Full Text] [Related]  

  • 13. Even for a minimalist, EPO has clear value.
    Reynolds J
    Nephrol News Issues; 2007 Aug; 21(9):47, 49. PubMed ID: 17722855
    [No Abstract]   [Full Text] [Related]  

  • 14. Capturing Epogen overfill.
    Wiseman K
    Nephrol Nurs J; 2000 Aug; 27(4):407, 415. PubMed ID: 11276633
    [No Abstract]   [Full Text] [Related]  

  • 15. A lesson from the EPO mess: stop the cost shifting.
    Amerling R
    Nephrol News Issues; 2007 Jul; 21(8):52, 54-5, 68. PubMed ID: 17688232
    [No Abstract]   [Full Text] [Related]  

  • 16. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients.
    Chan K; Moran J; Hlatky M; Lafayette R
    Nephrol Dial Transplant; 2009 Jun; 24(6):1956-62. PubMed ID: 19176685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The normal hematocrit study--follow-up.
    Besarab A; Goodkin DA; Nissenson AR;
    N Engl J Med; 2008 Jan; 358(4):433-4. PubMed ID: 18216370
    [No Abstract]   [Full Text] [Related]  

  • 18. Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients.
    Chan KE; Lafayette RA; Whittemore AS; Hlatky MA; Moran J
    Nephrol Dial Transplant; 2008 Sep; 23(9):2948-56. PubMed ID: 18469314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has economics overshadowed our clinical approaches to EPO?
    Sullivan JD
    Nephrol News Issues; 2007 Jul; 21(8):56, 58-9, 68. PubMed ID: 17688233
    [No Abstract]   [Full Text] [Related]  

  • 20. Anemia and response to epoetin alfa: the cause of anemia matters!
    Dharmarajan TS
    J Am Geriatr Soc; 2008 Aug; 56(8):1574-5. PubMed ID: 18808607
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.